TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Tenaya Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$0.38−0.00 (-0.81%)

Close on Oct 19, 2026

Market cap: $82.16M
P/E (TTM): –
Dividend yield: –

Tenaya Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	69	87	98	95	54	31
General & Administrative	25	29	33	31	18	7.81
Operating Expenses	93	116	131	126	73	39
Operating Income	-93	-116	-131	-126	-73	-39
Interest & Investment Income	2.68	4.74	7.06	1.95	0.11	0.09
Other Non-Operating Income	2.73	4.82	7.11	1.96	0.09	0.52
Gain (Loss) on Sale of Assets	–	–	–	–	-0.06	-0.03
Pretax Income	-91	-111	-124	-124	-73	-38
Income Tax Expense	0	0	0	0	0	0
Net Income incl. Noncontrolling Interests	-91	-111	-124	-124	-73	-38
Net Income	-91	-111	-124	-124	-73	-38
EPS (Basic)(per share)	-0.59	-1.31	-1.68	-2.76	-4.10	-39.50
EPS (Diluted)(per share)	-0.59	-1.31	-1.68	-2.76	-4.10	-39.50
Shares Outstanding (Basic, Weighted)(shares)	153	85	74	45	18	0.97
Shares Outstanding (Diluted, Weighted)(shares)	153	85	74	45	18	0.97
EBITDA	-85	-107	-123	-119	-70	-36

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -83.8%

Financial strength

Current ratio: 4.52
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 410.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.18
Dividend yield: –